Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Ovarian cancer patients with many folate receptors benefit from new therapy

A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.

29 Oct 2011

BROCA test identifies 12 gene mutations linked to ovarian and related cancers

More patients with ovarian carcinoma carry cancer-predisposing mutations, and in more genes, than previously thought.

27 Oct 2011

Taking the Pill for 10 years can reduce risk of ovarian cancer by almost half

Taking the Pill for 10 years can reduce the risk of ovarian cancer by almost half (45 per cent), new research part-funded by Cancer Research UK shows today.

27 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

Women to benefit from new TFRI ovarian cancer initiative

Women throughout the world will benefit from a new, pan-Canadian Terry Fox Research Institute (TFRI) initiative that aims to change the way in which ovarian cancer is diagnosed and managed.

14 Oct 2011

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Manhattan Scientifics announced today that the National Cancer Institute (NCI) has funded a grant for its Senior Scientific, LLC unit, for the use of its proprietary, highly precise magnetic cancer cell measurement in leukemia research for determining the progress of cancer treatment.

14 Oct 2011

Ovarian cancer patients survive longer with BRCA2 mutation in tumors

Among women with a certain type of high-grade ovarian cancer, having BRCA2 genetic mutations, but not BRCA1, was associated with improved overall survival and improved response to chemotherapy, compared to women with BRCA wild-type, according to a study in the October 12 issue of JAMA.

12 Oct 2011

FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.

12 Oct 2011

Scientists identify 16M SNPs that associate with risk of gout, serum uric acid levels

Scientists at deCODE Genetics and academic collaborators from Iceland, Norway, Denmark, the Netherlands and the USA report the discovery of low frequency variants in the human genome that associate with risk of gout, a common inflammatory arthritis, and serum uric acid levels.

10 Oct 2011

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

A new study released this Wednesday revealed that breast cancer that is highly aggressive but caught early could be best treated with a combination of Herceptin and chemotherapy.

6 Oct 2011

Many average-risk women receive genetic testing for hereditary breast, ovarian cancers

Too many average-risk women and too few high-risk women receive genetic counseling and testing for hereditary breast and ovarian cancers, research shows. Experts at The University of Texas MD Anderson Cancer Center share advice to help patients and their doctors better evaluate family history and make more sound decisions about who should be tested.

4 Oct 2011

CCP announces eight new cancer research projects at BWH

The Campaign for Cancer Prevention (CCP) began in 2007 with the single goal of uniting those across the globe who care about preventing cancer. It has now grown to a more than 6 million member movement, becoming a leading initiative on the social media platform, Causes.com.

4 Oct 2011

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

EntreMed, Inc., a clinical stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the final data for the primary endpoint of progression free survival rate at 6 months for its Phase 2 study with ENMD-2076 in platinum-resistant ovarian cancer patients.

3 Oct 2011

Scientists discover 16 million SNPs that associate with increased risk of ovarian cancer

Scientists at deCODE Genetics and academic collaborators from Iceland, The Netherlands, Spain and Finland today report the discovery of variants in the human genome that associate with increased risk of invasive ovarian cancer, one of the deadliest forms of cancer in women.

3 Oct 2011

No link between chemotherapy during pregnancy and children's cognitive development

Children born after their mothers were treated with chemotherapy during pregnancy appear to be unaffected by the experience in terms of the development of their mental processes and the normal functioning of their hearts, according to new research presented at the 2011 European Multidisciplinary Cancer Congress.

27 Sep 2011

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Aeterna Zentaris Inc., today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108.

26 Sep 2011

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

Cannabidiol—a compound derived from marijuana—may be a promising new treatment to prevent the development of painful neuropathy in patients receiving the chemotherapy drug paclitaxel, according to animal experiments reported in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Sep 2011

Komen Foundation grant enables TGen scientists to study triple-negative breast cancer

The Translational Genomics Research Institute (TGen) is part of a team of medical investigators receiving a $3.5 million grant from Susan G. Komen for the Cure to study triple-negative breast cancer, a highly aggressive form of this cancer that disproportionately affects African-Americans.

26 Sep 2011

Genetic testing for breast and ovarian cancer

Experts from Cancer Treatment Centers of America (CTCA) provide some clues as to who should be using these tests. They explain that women who have been diagnosed with cancer and/or people who have a strong family history of cancer can consider genetic testing. Red flags to consider are anyone in the family who developed cancer at a young age, multiple family members who developed cancer, if a person experienced bilateral cancer (cancer in both breasts), breast and ovarian cancer in the same woman, or cancer appeared where it wasn’t expected (like breast cancer in men)

26 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Ovarian cancer patients with many folate receptors benefit from new therapy

BROCA test identifies 12 gene mutations linked to ovarian and related cancers

Taking the Pill for 10 years can reduce risk of ovarian cancer by almost half

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Women to benefit from new TFRI ovarian cancer initiative

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Ovarian cancer patients survive longer with BRCA2 mutation in tumors

FDA grants Advaxis pre-IND meeting for ADXS-HER2 cancer immunotherapy

Scientists identify 16M SNPs that associate with risk of gout, serum uric acid levels

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

Many average-risk women receive genetic testing for hereditary breast, ovarian cancers

CCP announces eight new cancer research projects at BWH

EntreMed announces data from ENMD-2076 Phase 2 study in platinum-resistant ovarian cancer

Scientists discover 16 million SNPs that associate with increased risk of ovarian cancer

No link between chemotherapy during pregnancy and children's cognitive development

Positive interim data from Aeterna Zentaris' AEZS-108 Phase 1/2 study on prostate cancer

Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy

Komen Foundation grant enables TGen scientists to study triple-negative breast cancer

Genetic testing for breast and ovarian cancer

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in